Rubric Capital Management (New York)’s Amneal Pharmaceuticals AMRX Stock Holding History

Rubric Capital Management (New York)’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$176M	Sell	10,168,660 -868,929	-8%	-$11.9M	1.61%	19
2026 Q1	$137M	Sell	11,037,589 -1,297,352	-11%	-$17.4M	1.45%	18
2025 Q4	$155M	Hold	12,334,941	–	–	1.86%	14
2025 Q3	$123M	Buy	12,334,941 +624,609	+5%	+$5.61M	1.39%	16
2025 Q2	$94.7M	Buy	11,710,332 +974,355	+9%	+$7.35M	1.43%	21
2025 Q1	$90M	Buy	10,735,977 +14,199	+0.1%	+$119K	1.61%	18
2024 Q4	$84.9M	Hold	10,721,778	–	–	1.09%	18
2024 Q3	$89.2M	Hold	10,721,778	–	–	1.45%	14
2024 Q2	$68.1M	Buy	10,721,778 +1,179,830	+12%	+$7.49M	1.79%	18
2024 Q1	$57.8M	Buy	9,541,948 +1,541,948	+19%	+$8.7M	1.71%	22
2023 Q4	$48.6M	Buy	8,000,000 +3,975,500	+99%	+$17.7M	1.01%	24
2023 Q3	$17M	Buy	4,024,500 +1,423,121	+55%	+$5.31M	0.64%	39
2023 Q2	$8.06M	Buy	+2,601,379	New	+$5.54M	0.34%	50

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Rubric Capital Management (New York)'s AMRX Position: Q2 2026 in Review

Rubric Capital Management (New York) reduced its Amneal Pharmaceuticals (AMRX) stake by 7.9% in Q2 2026, selling an estimated $11.9M and leaving 10,168,660 shares worth $176M. The position accounts for 1.61% of the portfolio, ranked #19.

Rubric Capital Management (New York) first reported a position in AMRX in Q2 2023 and has held it in 13 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Rubric Capital Management (New York) held 10,168,660 shares of Amneal Pharmaceuticals worth $176M as of Q2 2026.
Rubric Capital Management (New York) sold 868,929 Amneal Pharmaceuticals shares in Q2 2026, an estimated $11.9M.
Amneal Pharmaceuticals made up 1.61% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #19 holding.
Rubric Capital Management (New York) first reported a position in Amneal Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.